Bernstein SocGen Lowers XPeng Price Target to $18
- Rating
- Market Perform
- Target
- $18
- from $20 (−10%)
- Upside
- +76%
- XPEV at $10.24 today

What the analyst said
Bernstein SocGen Group analyst Eunice Lee lowered the price target on XPeng (NYSE: XPEV) to $18 (from $20) while maintaining a Market Perform rating.
“Q2 losses widened on higher investments. XPeng reported Q2 revenue of RMB 19.7bn (+8.0% yoy and +51.5% qoq).
With vehicle revenue rising just 1% yoy, growth was primarily driven by services and other revenue, which nearly doubled yoy, including RMB1.2bn (Bern estimate) contribution from VW.
XPeng delivered 103k units, +0.1% yoy and +64.8% qoq, and ASP reached RMB 165k, +0.9% yoy and -6.0% qoq.
The sequential ASP decline primarily reflected a higher proportion of MONA M03 sales, partially mitigated by the launch of premium models (e.g.
GX) and strong momentum of overseas sales (over 20k deliveries in Q2 26 with ASP above €40k).
Overall gross margin held resilient at 20.7%, vs. 17.3% in Q2 25 and 20.6% in Q1 26, underpinned by steady vehicle margin (12.1%, vs.
14.3% in Q2 25 and 12.1% in Q1 26) and higher contribution from VW tech R&D service, and parts and accessories sales.
The yoy decline in vehicle margin was mainly attributable to rising raw material costs and a less favorable product mix.
Q2 26 R&D expenses reached RMB 2.9bn, increasing 32.1% yoy and 0.3% qoq, reflecting continued investment in new vehicle programs and AI development, while SG&A as a % of revenue reached 12.6% vs.
11.9% in Q2 25 and 14.5% in Q1 26.
Overall Opex ratio increased to 27.4% vs 23.9% in Q2 25 and 36.8% in Q1 26. As a result, XPeng recorded RMB-1.3bn net loss and -6.8% net margin, vs. -2.6% in Q2 25 and -13.7% in Q1 26.”
The price target and rating on this page are the opinion of the issuing research firm and its analyst, not of Price Target. This page is published for informational purposes only and is not investment advice, a recommendation, or an offer to buy or sell any security. Past performance does not guarantee future results. Consider your own circumstances and consult a licensed financial adviser before making investment decisions.
This research note is reproduced verbatim from the issuing firm. Price Target never edits, paraphrases or alters analysts’ words — we only republish them in one place.
Where the price stands
XPEV trades at $10.24. The 7 analysts who set a target in the last 3 months range from $10 to $22, with a median of $16. This $18 target is 13% above the median.
Since the note XPEV has moved −16% (from $12.19). 12-month window: day 74 of 365, closes on August 24, 2027.
Track record
This callOpen: XPEV has not reached $18 yet. This 12-month target is scored on August 24, 2027.
Firm track recordBernstein: 79% of its 24 targets at least a year old were reached within 12 months (#14 of 26 firms). Accuracy ranking →
Bernstein on XPeng
Bernstein price targets on XPeng
6 calls from August 20, 2025 to August 24, 2026. The target went from $21 to $18 (−14%). The rating stayed Hold.
- August 24, 2026 This noteTarget cut from $20 (−10%)Hold$18
- June 17, 2026Target cut from $22 (−9%)Hold$20
- March 23, 2026Target raised from $21 (+5%)Hold$22
- November 18, 2025Kept the $21 targetHold$21
- November 6, 2025Kept the $21 targetHold$21
- August 20, 2025Earliest call shownHold$21


